Ghent University Academic Bibliography

Advanced

Cost-utility analysis of ranibizumab (lucentis®) in wet-AMD based on real-life data collected in the HELIOS study after ranibizumab reimbursement in Belgium

K Moeremans, L Gerlier, S Drieskens, Lieven Annemans UGent, H Brie, M Deruyck, P Faes and S Vancayzeele (2011) VALUE IN HEALTH. 14(3). p.A55-A55
Please use this url to cite or link to this publication:
author
organization
alternative title
Cost-utility analysis of ranibizumab (lucentis (R)) in wet-AMD based on real-life data collected in the HELIOS study after ranibizumab reimbursement in Belgium
year
type
conference (meetingAbstract)
publication status
published
subject
in
VALUE IN HEALTH
Value Health
volume
14
issue
3
article number
abstract PSS14
pages
A55 - A55
conference name
ISPOR 16th Annual International Meeting
conference location
Baltimore, MD, USA
conference start
2011-05-21
conference end
2011-05-25
Web of Science type
Meeting Abstract
Web of Science id
000299105000290
JCR category
ECONOMICS
JCR impact factor
2.191 (2011)
JCR rank
31/320 (2011)
JCR quartile
1 (2011)
ISSN
1098-3015
language
English
UGent publication?
yes
classification
C3
copyright statement
I have transferred the copyright for this publication to the publisher
id
2153194
handle
http://hdl.handle.net/1854/LU-2153194
date created
2012-06-14 11:34:31
date last changed
2016-12-21 15:41:04
@inproceedings{2153194,
  articleno    = {abstract PSS14},
  author       = {Moeremans, K and Gerlier, L and Drieskens, S and Annemans, Lieven and Brie, H and Deruyck, M and Faes, P and Vancayzeele, S},
  booktitle    = {VALUE IN HEALTH},
  issn         = {1098-3015},
  language     = {eng},
  location     = {Baltimore, MD, USA},
  number       = {3},
  pages        = {abstract PSS14:A55--abstract PSS14:A55},
  title        = {Cost-utility analysis of ranibizumab (lucentis{\textregistered}) in wet-AMD based on real-life data collected in the HELIOS study after ranibizumab reimbursement in Belgium},
  volume       = {14},
  year         = {2011},
}

Chicago
Moeremans, K, L Gerlier, S Drieskens, Lieven Annemans, H Brie, M Deruyck, P Faes, and S Vancayzeele. 2011. “Cost-utility Analysis of Ranibizumab (lucentis®) in wet-AMD Based on Real-life Data Collected in the HELIOS Study After Ranibizumab Reimbursement in Belgium.” In Value in Health, 14:A55–A55.
APA
Moeremans, K., Gerlier, L., Drieskens, S., Annemans, L., Brie, H., Deruyck, M., Faes, P., et al. (2011). Cost-utility analysis of ranibizumab (lucentis®) in wet-AMD based on real-life data collected in the HELIOS study after ranibizumab reimbursement in Belgium. VALUE IN HEALTH (Vol. 14, pp. A55–A55). Presented at the ISPOR 16th Annual International Meeting.
Vancouver
1.
Moeremans K, Gerlier L, Drieskens S, Annemans L, Brie H, Deruyck M, et al. Cost-utility analysis of ranibizumab (lucentis®) in wet-AMD based on real-life data collected in the HELIOS study after ranibizumab reimbursement in Belgium. VALUE IN HEALTH. 2011. p. A55–A55.
MLA
Moeremans, K, L Gerlier, S Drieskens, et al. “Cost-utility Analysis of Ranibizumab (lucentis®) in wet-AMD Based on Real-life Data Collected in the HELIOS Study After Ranibizumab Reimbursement in Belgium.” Value in Health. Vol. 14. 2011. A55–A55. Print.